Fundz

INVO Bioscience

SARASOTA, FL · Biotechnology, Healthcare, Health Care · 19 employees

At INVO bioscience, we are democratizing fertility. Our mission is to help people realize the dream of parenthood by increasing worldwide access to an efficient, effective, and connected experience in reproductive treatment. We are the manufacturers of INVOcell. The first and only FDA cleared, CE marked medical device used in intravaginal culture (IVC). INVOcell holds the gametes within the woman’

Funding history

  • Series private placement — $4.0M — Dec 2025
  • Series seed — $3.0M — Apr 2023
  • Series seed — $500K — Mar 2023
  • Series seed — $300K — Feb 2023
  • Series seed — $500K — Jan 2023

Recent signals

  • May 17, 2026: Acquired INVO Bioscience to merge with NAYA Biosciences
  • Feb 19, 2026: Acquired INVO Fertility acquires Family Beginnings clinic
  • Dec 05, 2025: Raised $4.0M in Series private placement
  • Dec 02, 2025: SEC 8-K (1.01): On December 2, 2025, INVO Fertility, Inc. entered into a Securities Purchase Agreement with an institutional investor, agreeing to issue and sell securities worth approximately $4,000,000. This transaction involves the sale of 235,000 shares of common stock and warrants to purchase an additional 6,865,592 shares, which includes both pre-funded and common stock purchase warrants. The private placement aims to strengthen the company's capital structure and provide necessary funding for future operations and projects. This move is strategic for INVO Fertility as it seeks to expand its market presence and develop its offerings in the fertility sector.
  • Oct 06, 2025: SEC 8-K (1.01): On October 6, 2025, INVO Fertility, Inc. entered into a material definitive agreement involving the exercise of an Additional Investment Right by an institutional investor, resulting in the acquisition of 200 shares of Series C-2 Convertible Preferred Stock valued at $200,000. This agreement stems from a Securities Purchase Agreement established on January 3, 2024, with NAYA Therapeutics Inc., with INVO having participated via a Joinder Agreement on October 11, 2024. The exercise of this option adjusts the conversion price of the C-2 Preferred to $0.6643 per share, significantly impacting the company's financing structure and potential dilution of existing equity holders.
  • Aug 11, 2023: Acquired Invo Closes Acquisition Of Wisconsin Fertility Institute
  • Apr 06, 2023: Raised $3.0M in Series seed
  • Mar 06, 2023: Raised $500K in Series seed

See plans & pricing → Track INVO Bioscience’s funding, hiring, and signals — with verified contacts — on Fundz.